New drug combo tested for Tough-to-Treat bile duct cancer
NCT ID NCT05998447
Summary
This study tested the safety and effectiveness of a new drug called GEN-001 when given alongside an existing immunotherapy (pembrolizumab) for people with advanced bile duct cancer that had stopped responding to standard treatments. It aimed to find the best dose and see if the combination could help control the cancer. The trial was terminated early and involved a small group of 10 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ajou University Medical Center
Suwon, 16499, South Korea
-
Asan Medical Center
Seoul, Seoul, 05505, South Korea
-
Korea University Guro Hospital
Seoul, Seoul, 08308, South Korea
-
Samsung Medical Center.
Seoul, Seoul, 06351, South Korea
-
Seoul National University Hospital
Seoul, Seoul, 03080, South Korea
-
Severance Hospital
Seoul, Seoul, 03722, South Korea
Conditions
Explore the condition pages connected to this study.